Thitina Jimma

One thousand patients with primary myelofibrosis: the mayo clinic experience.

A. Tefferi, T. Lasho, R. Ketterling, 2012, Mayo Clinic proceedings.

SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival.

A. Tefferi, M. Patnaik, T. Lasho, 2012, Blood.

Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients.

A. Tefferi, D. Caramazza, A. Pardanani, 2011, Blood.

IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F

A. Tefferi, T. Lasho, A. Pardanani, 2011, Leukemia.

SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients

A. Tefferi, R. Ketterling, A. Pardanani, 2012, Leukemia.

Plasma cytokines in polycythemia vera: Phenotypic correlates, prognostic relevance, and comparison with myelofibrosis

A. Tefferi, T. Lasho, A. Pardanani, 2012, American journal of hematology.

Vitamin D insufficiency in myeloproliferative neoplasms and myelodysplastic syndromes: Clinical correlates and prognostic studies

A. Tefferi, T. Lasho, M. Drake, 2011, American journal of hematology.